The ARRB2 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of HT29 human colorectal adenocarcinoma cells with targeted disruption of the ARRB2 gene, eliminating ??-arrestin-2 expression. This polyclonal pool provides a heterogeneous loss-of-function model ideal for pooled screens and phenotypic analyses while minimizing clonal artifacts. It enables robust investigation of ??-arrestin-2 functions in cancer signaling.
The HT29 cell line is a well-characterized human colorectal adenocarcinoma model with epithelial morphology, widely used to study intestinal epithelial biology, absorptive functions, and colorectal cancer. HT29 cells harbor mutations in APC, TP53, and KRAS, driving constitutive Wnt/??-catenin and MAPK pathway activity, and can differentiate into enterocyte-like cells under specific conditions, offering a versatile platform for colorectal tumorigenesis research.
ARRB2 encodes ??-arrestin-2, a scaffold protein that mediates GPCR desensitization and clathrin/AP-2-dependent internalization while acting as an adaptor for MAPK/ERK signaling. Recruited to activated GPCRs such as ADRB2 and CXCR4 by GRK2, ??-arrestin-2 assembles signaling complexes containing Src, ERK, JNK, and PI3K. It also bridges GPCR signals to the Wnt/??-catenin pathway by interacting with Dishevelled (DVL) and stabilizing ??-catenin, promoting TCF/LEF transcriptional activity. Additionally, ??-arrestin-2 modulates NF-??B via TRAF6 and influences TGF-?? signaling through Smad2/3 interactions, thereby integrating proliferative, survival, and migratory cues.
In HT29 cells, ARRB2 knockout disrupts desensitization of GPCRs and simultaneously impairs MAPK/ERK and Wnt/??-catenin signaling, leading to reduced proliferation, migration, and invasion. This model is instrumental for studying colorectal cancer progression, inflammatory bowel disease-associated carcinogenesis, and metastasis. Moreover, disruption of NF-??B and TGF-?? pathways offers a tool to investigate immune evasion and tumor microenvironment interactions.
Key applications include Western blotting and RT-qPCR for target validation, MTT proliferation assays, wound healing and Transwell migration/invasion studies, TCF/LEF reporter assays to assess Wnt activity, phospho-ERK analysis, co-immunoprecipitation to probe protein interactions, and drug sensitivity testing. This model supports investigations into GPCR signaling in colorectal cancer, Wnt regulation, cell motility, drug response, and immune evasion. For further information, please contact Ascent Research.
